This article was originally published on this site
Trovagene (TROV) had a good day on the market for Tuesday March 13 as shares jumped 23.14% to close at $0.46. About 8.06 million shares traded hands on 6,959 trades for the day, compared with an average daily volume of 1.73 million shares out of a total float of 55.29 million. After opening the trading day at $0.38, shares of Trovagene stayed within a range of $0.48 to $0.37.
With today’s gains, Trovagene now has a market cap of $25.6 million. Shares of Trovagene have been trading within a range of $1.90 and $0.24 over the last year, and it had a 50-day SMA of $0.33 and a 200-day SMA of $0.67.
TrovaGene Inc is clinical-stage, precision medicine oncology therapeutics company. Its focus is to develop oncology therapeutics for improved cancer care and to optimize drug development by leveraging its Precision Cancer Monitoring technology.
Trovagene is based out of San Diego, CA and has some 17 employees. Its CEO is William J. Welch.
For a complete fundamental analysis of Trovagene, check out Equities.com’s Stock Valuation Analysis report for TROV.
Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit http://www.equitiespremium.com/ to learn more about Guild Investment’s Market Commentary and Adam Sarhan’s Find Leading Stocks today.
Trovagene is also a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
To get more information on Trovagene and to follow the company’s latest updates, you can visit the company’s profile page here: TROV’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.com’s Newsdesk. Also, don’t forget to sign-up for our daily email newsletter to ensure you don’t miss out on any of our best stories.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer